Solara Active Pharma Sciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Currently loss-making (EPS ₹-1.7)
- Negative return on equity (ROE -0.1%)
- Low capital efficiency (ROCE 4.9%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SOLARA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 30.49% | 30.49% | 37.27% | 37.27% | 37.23% | 37.94% |
| FII | 16.62% | 15.80% | 14.00% | 14.25% | 14.67% | 14.63% |
| DII | 1.75% | 2.97% | 2.83% | 3.37% | 3.19% | 2.61% |
| Public | 51.14% | 50.73% | 45.89% | 45.11% | 44.92% | 44.82% |
Latest News
All newsSolara Pharma Q2 revenue up 33%, EBITDA more than doubles
*Solara Pharma Q2 revenue up 33%, EBITDA more than doubles*. Company reported **₹4,178 crore** revenue and **₹769 crore** EBITDA in Q2 FY27, marking its best quarter in five years. Strong performance driven by robust demand in key geographies and improved margins. Growth signals turnaround in operational efficiency and market positioning. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Solara Active Pharma announces board meeting outcomes
*Solara Active Pharma announces board meeting outcomes*. The company disclosed outcomes from its recent board meeting, including updates on financials and operations. No major strategic decisions or financial surprises were revealed, with results aligned to expectations. The filing accompanies the limited review report for the quarter. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Solara Active Pharma sees spurt in trading volume
*Solara Active Pharma sees spurt in trading volume* — A significant increase in trading volume has been observed in Solara Active Pharma Sciences Limited, prompting an inquiry from the NSE to ensure market transparency. The exchange has sought updated information from the company to safeguard investor interests. No major corporate event or disclosure has been announced yet. 📊 *STOCKS:* SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #VolumeSpurt
Solara Pharma discusses Q1FY26 financial results
*Solara Pharma discusses Q1FY26 financial results* in its investor call. The company reviewed performance for the quarter ended June 30, 2026, highlighting revenue of **₹182.4 Cr** and EBITDA at **₹34.1 Cr**. Management discussed margin trends and R&D outlay of **₹12.5 Cr**. Guidance for FY26 exports reiterated at **$115–120 Mn**. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Solara launches ESOP/ESOS/ESPS 2024 plan for employees
*Solara launches ESOP/ESOS/ESPS 2024 plan for employees*. The company has introduced a new employee stock option plan to incentivize talent. The scheme is subject to shareholder approval and regulatory norms. Specific grant sizes or **₹ amounts not disclosed**. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP
Solara Pharma announces ESOP/ESOS/ESPS offering
*Solara Pharma announces ESOP/ESOS/ESPS offering.* This includes employee stock options and sweat equity schemes. No immediate financial impact is indicated. Such corporate actions are routine and aimed at employee retention. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP
Solara receives rectification order from regulator
*Solara receives rectification order from regulator*. Solara Active Pharma Sciences has informed the exchange about a rectification order received, pertaining to regulatory compliance. The nature of the order is procedural and does not indicate any adverse action. No financial impact or operational changes have been disclosed. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation